Table 1 Overview of FDA-approved CAR T Therapies
From: Steering the course of CAR T cell therapy with lipid nanoparticles
CAR product | CAR generation | Approval year | Company | Indication | Target antigen |
|---|---|---|---|---|---|
Tisagenlecleucel | 2nd 4-1BB co-stimulatory domain-based | 2017 | Kymriah® | R/R large BCL | CD19 |
Axicabtagene ciloleucel | 2nd-CD28 based | 2017 | Yescarta® | Post-first-line therapy; mediastinal large BCL, high-grade BCL, and lymphoma arising from follicles | CD19 |
Brexucabtagene autoleucel | 3rd-Synthetic notch receptor | 2020 | Tecartus® | Adults with R/R B-cell precursor ALL | CD19 |
Lisocabtagene maraleucel | 2nd-4-1BB co-stimulatory domain-based | 2021 | Breyanzi® | High-grade BCL, primary mediastinal large BCL, and follicular lymphoma grade 3B | CD19 |
Idecabtagene vicleucel | 3rd-encompassed an immunomodulator, an inhibitor of proteasome, and an anti-CD38 antibody | 2021 | Abecma® | Adults with MM experiencing R/R status following 4 or more previous lines of treatment | BCMA |
Ciltacabtagene autoleucel | 3rd-synthetic Notch receptor, encompassed an inhibitor of proteasome, an immunomodulator, and an anti-CD38 antibody | 2022 | Carvykti® | Adults with MM experiencing R/R status following 4 or more previous lines of treatment | BCMA |